Classement en actions
#24895
Orexo AB (publ), a specialty pharmaceutical company, develops and... Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis. Its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
Capitalisation boursière
$55.01M
Changement (1 jour)
0.00%
Changement (1 an)
-28.94%
Le prix ORX avec la capitalisation boursière de B
Capitalisation boursière de Orexo AB(ORX)
Capitalisation boursière: $55.01M
En August 2026, Orexo AB a une capitalisation boursière de $55.01M. Cela fait de Orexo AB la 24895th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Orexo AB du 2005 au 2026
ORX par rapport au top 5 des plus populaires stocks
| Prix pour ORX |
|
L’actif B |
La capitalisation boursière de B |
Résultats |
|
|
|
|
$5.257T
|
+9,556,678.03%
|
|
|
|
|
$4.599T
|
+8,360,093.75%
|
|
|
|
|
$4.107T
|
+7,465,529.21%
|
|
|
|
|
$3.577T
|
+6,503,225.57%
|
|
|
|
|
$2.807T
|
+5,103,486.09%
|
